Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
1. A pharmaceutical composition useful for topical, transdermal, subcutaneous, and/or intradermal treatment of skin wounds in a subject comprising:
a) a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide selected from the group consisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide, and a chimeric polypeptide thereof; and
b) a pharmaceutically acceptable carrier;
wherein the HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.
2. The pharmaceutical composition of claim 1 , wherein the HSV comprising the recombinant herpes simplex virus genome is replication-defective.
3. The pharmaceutical composition of claim 1 , wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in a herpes simplex virus gene.
4. The pharmaceutical composition of claim 3 , wherein the herpes simplex virus gene is selected from the group consisting of infected cell protein (ICP)0, ICP4, ICP22, ICP27, ICP47, thymidine kinase (tk), long unique region (UL)41, and UL55.
5. The pharmaceutical composition of claim 1 , wherein the recombinant herpes simplex virus genome comprises the one or more transgenes within one or more viral gene loci.
6. The pharmaceutical composition of claim 5 , wherein the recombinant herpes simplex virus genome comprises the one or more transgenes within one or more of the ICP4 viral gene loci.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is suitable for a route of administration selected from the group consisting of topical administration, transdermal administration, subcutaneous administration, intradermal administration, and any combinations thereof.
8. The pharmaceutical composition of claim 1 , wherein the recombinant herpes simplex virus genome comprises a transgene encoding a Collagen alpha-1 (VII) chain polypeptide.
9. The pharmaceutical composition of claim 8 , wherein the Collagen alpha-1 (VII) chain polypeptide has at least 80% sequence identity to the sequence of SEQ ID NO: 2.
10. The pharmaceutical composition of claim 8 , wherein the Collagen alpha-1 (VII) chain polypeptide enhances, increases, augments, and/or supplements anchoring fibril formation of a subject when the polypeptide is expressed in one or more target cells of the subject.
11. The pharmaceutical composition of claim 8 , wherein the Collagen alpha-1 (VII) chain polypeptide enhances, increases, augments, and/or supplements epithelial basement membrane organization and/or epithelial basement adherence of a subject when the polypeptide is expressed in one or more target cells of the subject.
12. A method of providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, the method comprising administering to the subject a pharmaceutical composition comprising:
a) a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide selected from the group consisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide, and a chimeric polypeptide thereof; and
b) a pharmaceutically acceptable carrier;
wherein the HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.
13. The method of claim 12 , wherein the HSV comprising the recombinant herpes simplex virus genome is replication-defective.
14. The method of claim 12 , wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in a herpes simplex virus gene.
15. The method of claim 14 , wherein the herpes simplex virus gene is selected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, and UL55.
16. The method of claim 12 , wherein the recombinant herpes simplex virus genome comprises the one or more transgenes within one or more viral gene loci.
17. The method of claim 16 , wherein the recombinant herpes simplex virus genome comprises the one or more transgenes within one or more of the ICP4 viral gene loci.
18. The method of claim 12 , wherein the pharmaceutically acceptable carrier is suitable for a route of administration selected from the group consisting of topical administration, transdermal administration, subcutaneous administration, intradermal administration, and any combinations thereof.
19. The method of claim 12 , wherein the recombinant herpes simplex virus genome comprises a transgene encoding a Collagen alpha-1 (VII) chain polypeptide.
20. The method of claim 19 , wherein the Collagen alpha-1 (VII) chain polypeptide has at least 80% sequence identity to the sequence of SEQ ID NO: 2.
21. The method of claim 19 , wherein the Collagen alpha-1 (VII) chain polypeptide enhances, increases, augments, and/or supplements anchoring fibril formation of a subject when the polypeptide is expressed in one or more target cells of the subject.
22. The method of claim 19 , wherein the Collagen alpha-1 (VII) chain polypeptide enhances, increases, augments, and/or supplements epithelial basement membrane organization and/or epithelial basement adherence of a subject when the polypeptide is expressed in one or more target cells of the subject.
23. The method of claim 12 , wherein the pharmaceutical composition is administered topically or transdermally to the subject.
24. The method of claim 12 , wherein the disease or disorder of the skin is one or more of epidermolysis bullosa, skin cancer, psoriasis, lichen planus, lupus, rosacea, eczema, cutaneous candidiasis, cellulitis, impetigo, decubitus ulcers, erysipelas, ichthyosis vulgaris, dermatomyositis, acrodermatitis, stasis dermatitis, nethertons syndrome, epidermolysis bullosa simplex (LAMB3 gene), autosomal recessive congenital ichthyosis, xeroderma pigmentosa, and pemphigoid.
25. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is a hydroxypropyl methylcellulose gel.
26. The composition of claim 1 , wherein the subject suffers from epidermolysis bullosa (EB).
27. The composition of claim 1 , wherein the subject is a human.
28. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is phosphate buffer.
29. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is suitable for topical administration.
30. The composition of claim 1 , wherein the HSV comprising the recombinant herpes simplex virus genome is replication-competent.
31. The method of claim 12 , wherein the pharmaceutically acceptable carrier is a hydroxypropyl methylcellulose gel.
32. The method of claim 12 , wherein the pharmaceutically acceptable carrier is phosphate buffer.
33. The method of claim 12 , wherein the pharmaceutically acceptable carrier is suitable for topical administration.
34. The method of claim 12 , wherein the disease or disorder of the skin is epidermolysis bullosa (EB).
35. The method of claim 12 , wherein the subject is a human.
36. The method of claim 12 , wherein the HSV comprising the recombinant herpes simplex virus genome is replication-competent.